Alzheimer’s treatment works best early, so why are patients waiting?

Two Alzheimer's drugs now slow the disease, and they work best when symptoms are still mild. Emer MacSweeney is a neuroradiologist and the cofounder and CEO of Re:Cognition Health. This episode is based on her article "Early Alzheimer's detection is now a treatment decision," published on KevinMD. She explains why she calls this a new era, how a simple blood test can start the workup, and why clearing amyloid early matters for the tau protein that tracks symptoms. You will hear what the trials showed: The mildest patients had no decline over the first year, and treatment slows the move from one stage to the next by about half. She makes the case that staying in the mild stage keeps patients eligible for the next medications in the pipeline. She also takes on the cost question, since these drugs slow decline rather than cure it, drawing on patients she treats who are fit, active, and often still working. Press play to hear why she says the biggest risk is not getting treated.

If this episode helped, follow The Podcast by KevinMD on Apple Podcasts or Spotify, and leave a rating.

Partner with me on the KevinMD platform. With more than 100 million impressions a year and nearly 750,000 followers, subscribers and email recipients across my channels, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story.

PARTNER WITH KEVINMD → https://kevinmd.com/influencer

SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast